Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
MBMoleculin Biotech, Inc. logo

Moleculin Biotech, Inc. (MBRX)

NASDAQ Capital Market · Currency in USD
$6.50 ▲ +0.61 (+10.36%)
At close: Oct 23, 4:00 PM ET. Market closed.
$6.58 ▲ +0.08 (+1.28%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$5.89
Open
$6.05
Day's Range
$5.65 – $6.50
52 Week Range
$3.22 – $315.00
Volume
26,891
Avg. Volume
62,850
Market Cap
$6.63M
Beta (5Y Monthly)
2.00
PE Ratio (TTM)
--
EPS (TTM)
-$106.77
Earnings Date
Nov 12, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
--

Profile: Moleculin Biotech, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
17
CEO
Walter V. Klemp

Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs.

Earnings

Next report: Thu, Nov 12, 2026
EPS estimate -$8.87
DateEst.Actual
Aug 13, 2026-$31.00-$28.00Beat
May 12, 2026-$33.80-$3.54Beat
Mar 20, 2026-$122.27-$57.00Beat
Nov 14, 2025-$4.00-$17.02Miss
Aug 12, 2025-$9.75-$12.25Miss
May 14, 2025-$14.20-$13.80Beat

Analyst view

Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on MBRX and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.